Insmed reported $212.58M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Cytokinetics USD 122.12M 2.52M Sep/2025
DBV Technologies USD 11.65M 1000 Mar/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Gilead Sciences USD 1.24B 0 Sep/2025
Insmed USD 212.58M 210.76M Sep/2025
Novartis USD 1.92B 17.06M Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025